Results 51 to 60 of about 53,616 (262)

A self-adjuvanted, modular, antigenic VLP for rapid response to Influenza virus variability.

ACS Applied Materials and Interfaces, 2020
The continuous evolution of influenza A virus (IAV) requires the influenza vaccine formulations to be updated annually to provide adequate protection.
Jhanvi Sharma, K. Shepardson, L. Johns, Julia Wellham, John Avera, B. Schwarz, A. Rynda-Apple, T. Douglas   +7 more
semanticscholar   +1 more source

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine

iScience
Summary: Continuing emergence of variants of concern resulting in reduced SARS-CoV-2 vaccine efficacy necessitates additional prevention strategies. The structure of VLPCOV-01, a lipid nanoparticle-encapsulated, self-amplifying RNA COVID-19 vaccine with ...
Masayuki Aboshi, Kenta Matsuda, Daisuke Kawakami, Kaoru Kono, Yoko Kazami, Takashi Sekida, Mai Komori, Amber L. Morey, Shigeru Suga, Jonathan F. Smith, Takasuke Fukuhara, Yasumasa Iwatani, Takuya Yamamoto, Nobuaki Sato, Wataru Akahata   +14 more
doaj   +1 more source

Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV

Viruses, 2019
Human cytomegalovirus (HCMV) infects more than 70% of the human population worldwide. HCMV is responsible for high morbidity and mortality in immunocompromised patients and remains the leading viral cause of congenital birth defects. Despite considerable
Michela Perotti, Laurent Perez
doaj   +1 more source

Pigs Immunized with the Virus-like Particle Vaccine Are Protected against the Hepatitis E-3 Virus

Vaccines, 2021
In this study, we generated the HEV virus-like particle (VLP) vaccine expressing 239 amino acids (367–605 aa) of the HEV-3 ORF2 using the baculovirus expression system.
Hyeon-Jeong Go, Byung-Joo Park, Hee-Seop Ahn, Dong-Hwi Kim, Da-Yoon Kim, Jae-Hyeong Kim, Joong-Bok Lee, Seung-Yong Park, Chang-Seon Song, Sang-Won Lee, Yang-Kyu Choi, In-Soo Choi   +11 more
doaj   +1 more source

Phase and antigenic variation in mycoplasmas [PDF]

, 2010
With their reduced genome bound by a single membrane, bacteria of the Mycoplasma species represent some of the simplest autonomous life forms. Yet, these minute prokaryotes are able to establish persistent infection in a wide range of hosts, even in the ...
Baranowski, Eric, Citti, Christine, Nouvel, Laurent-Xavier   +2 more
core   +2 more sources

Immunogenicity and protective efficacy of human metapneumovirus virus-like particles produced by a recombinant baculovirus in mice

Virus Research, 2023
Background: Human metapneumovirus (HMPV) causes respiratory tract infections among infant, elderly, and immunocompromised patients, with significant mortality. Currently no licensed vaccines or therapeutic agents of HMPV exist.
Fenlian Ma, Aijun Chen, Lihong Yao, Hanchun Gao, Qian Zhang, Wenzhe Hou, Lishu Zheng   +6 more
doaj   +1 more source

Alterations of membrane curvature during influenza virus budding [PDF]

, 2014
Influenza A virus belongs to the Orthomyxoviridae family. It is an enveloped virus that contains a segmented and negative-sense RNA genome. Influenza A viruses cause annual epidemics and occasional major pandemics, are a major cause of morbidity and ...
Agnieszka Martyna, Ali, Brown, Bruce, Chen, Enami, Gomez-Puertas, Jeremy Rossman, Johnson, Lai, Leser, Liao, Liu, McCown, McCown, Palese, Pattnaik, Pinto, Rossman, Rossman, Rossman, Rossman, Ruigrok, Schmidt, Takeda, Wang, Wang, Watanabe, Zebedee, Zhang   +29 more
core   +1 more source

Molecular pharming — VLPs made in plants

Current Opinion in Biotechnology, 2016
Plant-based expression offers a safe, inexpensive and potentially limitless way to produce therapeutics in a quick and flexible manner. Plants require only simple inorganic nutrients, water, carbon dioxide and sunlight for efficient growth. Virus-like particles (VLPs) are convincing look-alikes of viruses but without carrying infectious genomic ...
Marsian, Johanna, Lomonossoff, George P
openaire   +2 more sources

A study of the safety and immunogenicity of a new vaccine for the prevention of COVID-19 based on virus-like particles in phase I clinical trials

Журнал микробиологии, эпидемиологии и иммунобиологии
Introduction. One of the more promising developments in preventing the spread of infections, including COVID-19, is the production of vaccines based on virus-like particles (VLP).
Tatiana V. Grebennikova, Olga N. Zaykova, Alexey A. Plotnikov, Lyudmila V. Kostina, Yana Yu. Chernoryzh, Olesia V. Eliseeva, Oleg E. Latyshev, Viktor F. Larichev, Irina T. Fedyakina, Milana A. Losich, Ilya M. Kirillov, Ilya E. Filatov, Marina V. Balandina, Valery V. Tsibezov, Kirill I. Yurlov, Ekaterina I. Lesnova, Valeria M. Kondratieva, Alina A. Kozlova, Marina S. Baranets, Aleksandr L. Gintsburg   +19 more
doaj   +1 more source

Characterization of a RS-LiDAR for 3D Perception

, 2017
High precision 3D LiDARs are still expensive and hard to acquire. This paper presents the characteristics of RS-LiDAR, a model of low-cost LiDAR with sufficient supplies, in comparison with VLP-16.
Liao, Qinghai, Liu, Ming, Liu, Yang, Wang, Lujia, Wang, Zhe, Ye, Haoyang   +5 more
core   +2 more sources